Synthesis of novel benzimidazole–oxadiazole derivatives as potent anticancer activity
作者:Ulviye Acar Çevik、Derya Osmaniye、Betül Kaya Çavuşoğlu、Begüm Nurpelin Sağlik、Serkan Levent、Sinem Ilgin、Nafiz Öncü Can、Yusuf Özkay、Zafer Asım Kaplancikli
DOI:10.1007/s00044-019-02451-0
日期:2019.12
this work, a series of novel 2-[(5-(4-(5(6)-substituted-1H-benzimidazol-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)thio]-1-(4-substitutedphenyl)ethan-1-ones (4a–4s) derivatives have been synthesized and evaluated for DNA Topo I inhibition and cytotoxicity. The structures of the compounds (4a–4s) were confirmed by IR, 1H-NMR, 13C-NMR, 2D NMR, and mass spectroscopy. Anticancer activity of these compounds was
DNA拓扑异构酶I在许多细胞代谢过程中调节DNA拓扑结构,是开发抗肿瘤药物的有效靶点。在这项工作中,一系列新颖的2-[((5-(4-(5(6)-取代的-1 H-苯并咪唑-2-基)苯基] -1,3,4-恶二唑-2-基)硫基合成了] -1-(4-取代苯基)乙-1-酮(4a-4s)衍生物,并评估了其对DNA Topo I的抑制作用和细胞毒性。化合物(4a–4s)的结构通过IR,1 H-NMR,13确认C-NMR,2D NMR和质谱。评估了这些化合物对两种不同的人类癌细胞系A549(人类肺腺癌)和HepG2(人类肝癌细胞系)以及正常小鼠胚胎成纤维细胞(NIH3T3)的抗癌活性。IC 50个的化合物的值图4a,图4c,和4 ˚F均较展出的参考药物顺铂最高。然后,抑制作用4a,4c和4 f使用琼脂糖凝胶电泳对超螺旋DNA进行了弛豫分析,研究了拓扑异构酶I酶上的化合物。膜联蛋白V-FITC测定法证明这些化合物通过凋亡诱导细胞死亡。